INOVIQ (ASX: IIQ) has reported superior efficacy from an in vitro study of CAR-exosomes cancer therapy that killed almost 88% ...

I n February 2025, it was revealed that a woman who as a child had undergone treatment for neuroblastoma was still ...

Jacob E. Berchuck, MD, discusses research on plasma epigenomic profiling in metastatic castration-resistant prostate cancer.

ABOUT ORPHAN DRUG DESIGNATION The FDA grants Orphan Drug Designation to investigational drugs intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S. Benefits ...

SunRock Biopharma and Escugen have joined forces in a strategic partnership to co-develop SRB123, a First-in-Class ...

GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

The Calibr-Skaggs Institute for Innovative Medicines , the drug development division of Scripps Research, today announced a milestone in ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

For men who undergo radiation therapy for prostate cancer, bowel problems are a common complication. This is due to the ...

With the weather finally warming up and tempting people to get outside, a dermatologist is sharing a reminder to protect our ...